12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tysabri natalizumab: Interim postmarketing study data

Interim data from the prospective, U.S. STRATIFY-2 trial in >35,000 patients receiving Tysabri showed that the incidence of progressive multifocal leukoencephalopathy (PML) was significantly lower in patients who tested negative for anti-JCV antibodies vs. anti-JCV antibody positive patients (p=0.0004). At baseline, the overall prevalence of anti-JCV antibodies was...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >